You are here: Industry Insights > Integral Molecular

News List

Integral Molecular, AstraZeneca Enter Oncology Antibody Alliance ContractPharma
November 04, 2021
Integral Molecular, a developer of antibodies against membrane proteins, entered an exclusive worldwide antibody license agreement with AstraZeneca to develop therapeutics for multiple cancers.
Integral Molecular's Extensive Collection of SARS-CoV-2 Reporter Virus Variants Supports the Clinical Development of Vaccines and MAbs Against Coronavirus prnewswire
August 19, 2021
To aid in the clinical development of new vaccines and monoclonal antibodies (MAbs) effective against emerging and highly infectious coronavirus variants, Integral Molecular has produced the most extensive catalog of SARS-CoV-2 pseudotyped reporter virus
Integral Molecular Develops Test for Neutralizing COVID-19 Antibodies americanpharmaceuticalreview
May 07, 2020
Integral Molecular announces the launch of SARS-CoV-2 Reporter Virus Particles (RVPs).
Integral Molecular to work on coronavirus vaccine research pharmaceutical-technology
March 12, 2020
US-based biotechnology company Integral Molecular will leverage its technology platforms to identify Covid-19 vaccines and therapeutics.
Integral Molecular Awarded $1.4 Million by NIH americanpharmaceuticalreview
December 05, 2018
Integral Molecular was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic.....
Integral Molecular begins immuno-oncology therapeutic targets discovery pharmaceutical-technology
June 19, 2017
US-based research-driven biotechnology company Integral Molecular has begun a therapeutic target discovery programme in immuno-oncology by utilising its membrane proteome array technology to identify cell-surface proteins...